Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous Cancers

NCT05896839 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05896839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05896839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous Cancers
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 24, 2024
Completion date
August 2, 2027
Enrollment
16 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iii cutaneous melanoma ajcc v8, clinical stage iii cutaneous merkel cell carcinoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, clinical stage iv cutaneous merkel cell carcinoma ajcc v8, metastatic basal cell carcinoma, metastatic carcinoma in the skin, metastatic melanoma, metastatic merkel cell carcinoma, metastatic skin squamous cell carcinoma, unresectable basal cell carcinoma, unresectable melanoma, unresectable merkel cell carcinoma, unresectable skin squamous cell carcinoma